Abstract
Patients with advanced cancer often suffer from cachexia, a debilitating and complex extreme weight loss syndrome which is also associated with shorter survival times. A pragmatic randomised controlled trial was conducted to determine whether an oral nutritional supplement containing the omega-3 fatty acid eicosapentaenoic acid (EPA) was able to improve quality of life and survival times of patients with advanced solid tumour cancer in a mixed tumour cancer type population.
Original language | English |
---|---|
Pages (from-to) | 1-8 |
Number of pages | 8 |
Journal | BAOJ Palliative medicine |
Volume | 1 |
Issue number | 1 |
Publication status | Published - 24 Apr 2015 |